Quantcast
Last updated on April 18, 2014 at 8:17 EDT

Latest Paclitaxel Stories

2013-05-13 16:27:24

SAN DIEGO and IRVINE, Calif., May 13, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today the acquisition of exclusive distribution rights from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation, to Cynviloq(TM) (marketed as Genexol-PM® in South Korea) in the 27 countries of European Union (EU). IGDRASOL had previously obtained the exclusive U.S. distribution rights to Cynviloq(TM) from Samyang, and with this agreement,...

2013-05-06 08:31:08

BUFFALO, N.Y., May 6, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Zenith Technology Corporation, through its affiliate ZenRx, announced today the execution of a collaborative licensing agreement granting Zenith Technology commercial rights to Oraxol and Oratecan in New Zealand and Australia. ZenRx will provide an upfront payment, milestones and royalties. Importantly, Zenith Technology Corporation will commit a significant amount of resources to the Oraxol and Oratecan global development...

2013-04-10 08:32:36

Study Presented at AACR 2013 Examines Bispecific Antibody in Combination with Paclitaxel and Trastuzumab CAMBRIDGE, Mass., April 10, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was presented as part of the American...

2013-04-08 00:20:36

IGDRASOL will present updates on its proprietary late clinical stage NBN-Pac formulations, including Cynviloq(TM), a paclitaxel nanoparticle, and the recently acquired IG-004, a vitamin E-based paclitaxel emulsion. Highlights of the findings include the studies and comparison of pharmacokinetic and pharmacodynamic properties as well as drug release characteristics to Abraxane®, an albumin-based paclitaxel nanoparticle (nab-paclitaxel). SAN DIEGO and FOUNTAIN VALLEY, Calif., April...

2013-04-01 00:20:20

IGDRASOL will present updates on Cynviloq(TM), its late clinical stage paclitaxel nanoparticle formulation. Highlights include the therapeutic evaluation of Cynviloq(TM) in poorly perfused tumors as well as the potential development of Cynviloq(TM)-based personalized paclitaxel cancer therapy. SAN DIEGO and FOUNTAIN VALLEY, Calif., March 31, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its...

2013-03-14 08:28:16

CALGARY, March 14, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the  year ended December 31, 2012. "We were very pleased to present our first randomized clinical data from our head and neck cancer clinical study in 2012," said Dr. Brad Thompson, President and CEO of Oncolytics. "In addition, in order to support our program, which now includes seven...

2013-03-07 08:28:01

Transaction establishes a pipeline led by IGDRASOL's late clinical stage paclitaxel-loaded micellar product candidate and enables the combination of IGDRASOL's additional proprietary formulation technology with Sorrento's G-MAB® antibody libraries as a broad platform for next-generation targeted therapeutics. SAN DIEGO and FOUNTAIN VALLEY, Calif., March 7, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to...

2013-03-05 08:28:09

CALGARY, March 5, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016). This trial is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN given intravenously...

2013-01-31 04:21:35

SEATTLE, Jan. 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIO(TM )(paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis. CTI remains blinded to the interim analysis results. GOG-0212...

2013-01-23 10:47:37

Virginia G. Piper Cancer Center data presented at San Francisco ASCO symposium A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study was led by physicians from Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a...